top of page



Accueil: Our technology

TATUM is a therapeutic company advancing next generation  immunotherapies. Using a modular synthetic biology platform, we develop multimodal nanofilaments igniting complete antitumor immune responses providing unparalleled tumor clearance efficacy.

Accueil: The team

Founding team

Kevin Neil, PhD
Co-Founder & CSO


Sébastien Rodrigue, PhD
Co-Founder & CTO

Prof. Université de Sherbrooke

Business advisors


General Partner & CMO
TVM Capital Life Science VC


Director Equity Analyst Healthcare at UBP, Geneva

Scientific advisors

Jamie Scott.jpg

Jamie Scott, MD, PhD

Prof. Emerita

Simon Fraser University

L Gagnon.jpg

CSO Ingenew Pharma

Medical Advisors

Photo kaufman.jpg

CEO of Ankyra Therapeutics

Clinical AssociateClinical Associate
Massachusetts General Hospital


Head of the Inpatient Unit in the Drug Development Department at the Gustave Roussy Cancer Campus. 


Director of the Department of Oncology at the Montréal Jewish General Hospital and director of McGill University’s Centre for Translational Research in Cancer. 

Accueil: Contact

Let's get in touch.

Are you interested in collaborating with us? Feel free to contact us. We are looking forward to hearing from you!

Thank you for contacting us!

Join us to create disruptive drugs!

We are constantly looking for talented individuals who are eager to hack biology and develop next-generation drugs.

If you want to join the team at TATUM, please send your CV and motivation letter at:

Jobs_Email .jpg
bottom of page